Myriad Genetics (MYGN) 10-Q 7 Feb 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Dec. 31, 2017	Feb. 01, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Trading Symbol	MYGN
Entity Registrant Name	MYRIAD GENETICS INC
Entity Central Index Key	899,923
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		69,850,295

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2017	Jun. 30, 2017
Current assets:
Cash and cash equivalents	$ 88.7	$ 102.4
Marketable investment securities	54.8	48.3
Prepaid expenses	9.8	12.7
Inventory	38.2	42.2
Trade accounts receivable, less allowance for doubtful accounts of $9.5 December 31, 2017 and $8.2 June 30, 2017	121.1	105.6
Prepaid taxes	8.4	0.2
Other receivables	6	5.7
Total current assets	327	317.1
Property, plant and equipment, net	48.4	51.1
Long-term marketable investment securities	58.5	48.5
Intangibles, net	475.2	491.6
Goodwill	319.4	316.1
Total assets	1,228.5	1,224.4
Current liabilities:
Accounts payable	25.1	22
Accrued liabilities	60.8	65.6
Short-term contingent consideration	70	127.3
Deferred revenue	3.4	2.6
Total current liabilities	159.3	217.5
Unrecognized tax benefits	33.4	25.2
Other long-term liabilities	6.6	7.2
Contingent consideration	11	13.2
Long-term debt	43.2	99.1
Long-term deferred taxes	60.8	84.4
Total liabilities	314.3	446.6
Commitments and contingencies
Stockholders’ equity:
Common stock, 69.4 and 68.4 shares outstanding at December 31, 2017 and June 30, 2017 respectively	0.7	0.7
Additional paid-in capital	871.1	851.4
Accumulated other comprehensive loss	(2.4)	(5.5)
Retained earnings (deficit)	44.8	(68.4)
Total Myriad Genetics, Inc. stockholders’ equity	914.2	778.2
Non-Controlling Interest		(0.4)
Total stockholders' equity	914.2	777.8
Total liabilities and stockholders’ equity	$ 1,228.5	$ 1,224.4

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Millions, $ in Millions	Dec. 31, 2017	Jun. 30, 2017
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 9.5	$ 8.2
Common stock, shares outstanding	69.4	68.4

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Molecular diagnostic testing	$ 179.2	$ 183.9	$ 358	$ 348.9
Pharmaceutical and clinical services	14.8	12.6	26.2	25
Total revenue	194	196.5	384.2	373.9
Costs and expenses:
Cost of molecular diagnostic testing	37.7	37.4	73.9	71.6
Cost of pharmaceutical and clinical services	6.7	7	13.5	12.7
Research and development expense	16.8	18.6	34.6	38
Change in the fair value of contingent consideration	13	(3.8)	(60.2)	(3.2)
Selling, general, and administrative expense	115.4	120.3	230.5	232.2
Total costs and expenses	189.6	179.5	292.3	351.3
Operating income	4.4	17	91.9	22.6
Other income (expense):
Interest income	0.4	0.3	0.8	0.6
Interest expense	(0.7)	(2.6)	(1.7)	(3.3)
Other	(0.4)	(2.6)	(0.7)	(3.8)
Total other income (expense):	(0.7)	(4.9)	(1.6)	(6.5)
Income before income tax	3.7	12.1	90.3	16.1
Income tax provision	(28.4)	6.2	(22.8)	11.4
Net income	32.1	5.9	113.1	4.7
Net loss attributable to non-controlling interest			(0.1)
Net income attributable to Myriad Genetics, Inc. stockholders	$ 32.1	$ 5.9	$ 113.2	$ 4.7
Earnings per share:
Basic	$ 0.46	$ 0.09	$ 1.64	$ 0.07
Diluted	$ 0.45	$ 0.09	$ 1.59	$ 0.07
Weighted average shares outstanding:
Basic	69.3	68.2	68.9	68.5
Diluted	71.9	68.3	71.2	68.9

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net income attributable to Myriad Genetics, Inc. stockholders	$ 32.1	$ 5.9	$ 113.2	$ 4.7
Unrealized loss on available-for-sale securities, net of tax	(0.3)	(0.4)	(0.3)	(0.8)
Change in foreign currency translation adjustment, net of tax	0.1	(8)	3.4	(3.6)
Comprehensive income (loss)	31.9	(2.5)	116.3	0.3
Comprehensive income attributable to non-controlling interest	0	0	0	0
Comprehensive income (loss) attributable to Myriad Genetics, Inc. shareholders	$ 31.9	$ (2.5)	$ 116.3	$ 0.3

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income attributable to Myriad Genetics, Inc. stockholders	$ 113.2	$ 4.7
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	26.3	22.1
Non-cash interest expense	0.1	0.3
Gain (loss) on disposition of assets	0.1	(0.2)
Share-based compensation expense	13.3	15.2
Impairment of cost basis investment		2.5
Bad debt expense	16	18.1
Loss on extinguishment of debt		1.3
Deferred income taxes	(25.9)	2.9
Unrecognized tax benefits	8.2	0.6
Change in fair value of contingent consideration	(60.2)	(3.2)
Changes in assets and liabilities:
Prepaid expenses	2.9	8.3
Trade accounts receivable	(32.5)	(24.4)
Other receivables	1.4	(2.4)
Inventory	4.1	(10.4)
Prepaid taxes	(8.4)	(0.4)
Accounts payable	3	(2)
Accrued liabilities	(5.8)	(5)
Deferred revenue	0.7	0.5
Net cash provided by operating activities	56.5	28.5
CASH FLOWS FROM INVESTING ACTIVITIES
Capital expenditures	(3.7)	(3.9)
Acquisitions, net of cash acquired		(216.1)
Purchases of marketable investment securities	(61.3)	(49)
Proceeds from maturities and sales of marketable investment securities	45.2	108.9
Net cash used in investing activities	(19.8)	(160.1)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from common stock issued under share-based compensation plans	6.3	1
Net proceeds from revolving credit facility		204
Repayment of revolving credit facility	(56)
Net proceeds from term loan		199
Repayment of term loan		(200)
Fees paid for extinguishment of debt		(0.6)
Repurchase and retirement of common stock		(31.6)
Proceeds from non-controlling interest	0.3
Net cash provided by (used in) financing activities	(49.4)	171.8
Effect of foreign exchange rates on cash and cash equivalents	(1)	(0.7)
Net increase (decrease) in cash and cash equivalents	(13.7)	39.5
Cash and cash equivalents at beginning of the period	102.4	68.5
Cash and cash equivalents at end of the period	$ 88.7	$ 108

Basis of Presentation

Basis of Presentation	6 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	(1) BASIS OF PRESENTATION The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the “Company” or “Myriad”) in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The condensed consolidated financial statements herein should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2017, included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017. Operating results for the three and six months ended December 31, 2017 may not necessarily be indicative of results to be expected for any other interim period or for the full year. The consolidated financial statements include the accounts of the Company’s majority-owned subsidiary, Assurex Canada, Ltd. which is 85% owned by Assurex Health, Inc. (“Assurex”), a wholly owned subsidiary of the Company, and 15% owned by the Centre for Addiction and Mental Health. Assurex Canada, Ltd. is a consolidated subsidiary of Assurex Health, Inc. The value of the non-controlling interest represents the portion of Assurex Canada, Ltd.’s profit or loss and net assets that is not held by Assurex Health, Inc. The Company attributes comprehensive income or loss of the subsidiary between the Company and the non-controlling interest based on the respective ownership interest. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Reclassification in the Consolidated Statements of Operations In connection with the preparation of the financial statements for the three and six months ended December 31, 2017, the Company determined that the amounts for the change in the fair value of contingent consideration were improperly reported as a component of other income (expense) and should have been reported as a component of operating income on the consolidated statements of operations at December 31, 2016. As a result, for the three and six months ended December 31, 2016 total costs and expenses were overstated, causing operating income and total other income (expense) to be understated by $3.8 and $3.2 respectively. There was no impact to net income or earnings per share. The Company concluded that the error was not material to the consolidated statements of operations, but has elected to correct the error in the accompanying financial statements for consistent presentation. The classification error had no effect on the on the previously reported consolidated balance sheets, statements of comprehensive income or cash flows for the quarter ended December 31, 2016. New Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective beginning in the first quarter of fiscal 2020. Early adoption of ASU 2016-02 is permitted. ASU 2016-02 requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company’s management is currently evaluating the impact of adopting ASU 2016-02 on the Company’s consolidated financial statements. In May 2014, the FASB issued the converged standard on revenue recognition with the objective of providing a single, comprehensive model for all contracts with customers to improve comparability in the financial statements of companies reporting using International Financial Reporting Standards and U.S. GAAP. The standard contains principles that an entity must apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity must recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. An entity can apply the revenue standard retrospectively to each prior reporting period presented (full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings (modified retrospective method). The standard will be effective for the Company first quarter of fiscal 2019, with early adoption permitted for annual periods beginning after December 16, 2016. The Company plans to adopt the standard July 1, 2018 using the full retrospective method. The Company continues to assess the impact of this standard on its results of operations, financial position and cash flows. Based on its preliminary assessment, the Company expects the majority of the amounts that have historically been classified as bad debt expense, primarily related to patient responsibility, will be reflected as a reduction of the transaction price and therefore as a reduction in revenue. The Company anticipates an increase in the level of required financial statement disclosures due to the standard.

Acquisitions

Acquisitions	6 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Acquisitions	(2) ACQUISITIONS Assurex On August 31, 2016, the Company completed the acquisition of Assurex, pursuant to the Agreement and Plan of Merger (as amended, the “Merger Agreement”), dated August 3, 2016. Pursuant to the terms of the Merger Agreement, Myriad Merger Sub, Inc., a wholly owned subsidiary of the Company, was merged with and into Assurex, with Assurex continuing as the surviving corporation, and wholly owned subsidiary of Myriad. The Company acquired Assurex for total consideration of $351.6, net of cash acquired of $5.5, including a cash payment of $216.1, and two potential performance-based milestones totaling $185.0 with a fair value of $130.0. The fair value of the performance-based milestones was determined by using the Monte Carlo Method. Of the cash consideration, $19.1 was deposited into an escrow account to fund (i) any post-closing adjustments payable to Myriad based upon differences between the estimated working capital and the actual working capital of Assurex at closing, and (ii) any indemnification claims made by Myriad against Assurex within 18 months following closing. Total consideration transferred was allocated to tangible assets acquired and liabilities assumed based on their fair values as of the acquisition date including current adjustments as set forth below. The Company believes the acquisition establishes the foundation for our neuroscience business and leverages our existing preventative care business unit with the addition of a product, GeneSight, which has growth potential. These factors contributed to consideration transferred in excess of the fair value of Assurex’s net tangible and intangible assets acquired, resulting in the Company recording goodwill in connection with the transaction. During the three months ended September 30, 2017 there was a fair value increase as of the date of the acquisition to equipment totaling due to updated 3 rd Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. The allocation of consideration transferred is considered final as of September 30, 2017. The final purchase price allocation is as follows: Estimated Fair Value Current assets $ 18.2 Intangible assets 295.6 Equipment 1.9 Goodwill 121.1 Current liabilities (18.9 ) Deferred tax liability (66.3 ) Total fair value purchase price $ 351.6 Less: Contingent consideration (130.0 ) Less: Cash acquired (5.5 ) Total cash consideration transferred $ 216.1 Identifiable Intangible Assets The Company acquired intangible assets that consisted of developed technology which had an estimated fair value of $256.5 and a database with an estimated fair value of $39.1. The fair value of the developed technology was determined using a probability-weighted income approach that discounts expected future cash flows to present value. The fair value of the database was determined using a combination of the lost profits and replacement cost methods. The estimated net cash flows were discounted using a discount rate of 16% which is based on the estimated internal rate of return for the acquisition and represents the rate that market participants might use to value the intangible assets. The projected cash flows were based on key assumptions such as estimates of revenues and operating profits; the time and resources needed to recreate databases and product and commercial development and approval; the life of the commercialized product; and associated risks related to viability and product alternatives. The Company will amortize the intangible assets on a straight-line basis over their estimated useful lives of 17 years for the developed technology and 5 years for the database. This amortization is not deductible for income tax purposes. Goodwill The goodwill represents the excess of consideration transferred over the fair value of assets acquired and liabilities assumed and is attributable to the benefits expected from combining the Company’s research and commercial operations with Assurex’s. This goodwill is not deductible for income tax purposes. Change in goodwill for the period ended December 31, 2017 is shown below: Carrying amount Balance June 30, 2017 $ 119.2 Fair value adjustment to equipment (0.1 ) Non-controlling interest adjustment 0.2 Change in deferred tax liability 1.8 Ending balance December 31, 2017 $ 121.1 Pro Forma Information The unaudited pro-forma results presented below include the effects of the Assurex acquisition as if it had been consummated as of July 1, 2016, with adjustments to give effect to pro forma events that are directly attributable to the acquisition which includes adjustments related to the amortization of acquired intangible assets, interest income and expense, and depreciation. The unaudited pro forma results do not reflect any operating efficiency or potential cost savings which may result from the consolidation of Assurex. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operation of the combined company would have been if the acquisition had occurred at the beginning of the period presented nor are they indicative of future results of operations and are not necessarily indicative of results that might have been achieved had the acquisition been consummated as of July 1, 2016. Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Revenue $ 194.0 $ 196.5 $ 384.2 $ 385.4 Income from operations 4.4 13.2 91.9 12.4 Net income (loss) 32.1 5.9 113.2 (13.3 ) Net income (loss) per share, basic $ 0.46 $ 0.09 $ 1.64 $ (0.19 ) Net income (loss) per share, diluted $ 0.45 $ 0.09 $ 1.59 $ (0.19 ) To complete the purchase transaction, the Company incurred approximately $5.0 of acquisition costs, which were recorded as selling, general and administrative expenses for the year ended June 30, 2017. For the three and six months ended December 31, 2017, Assurex contributed revenue of approximately $31.7 and $60.5. For the three and six months ended December 31, 2017, operating expenses related to Assurex were approximately $29.2 and $58.9.

Marketable Investment Securitie

Marketable Investment Securities	6 Months Ended
	Dec. 31, 2017
Investments Debt And Equity Securities [Abstract]
Marketable Investment Securities	(3) MARKETABLE INVESTMENT SECURITIES The Company has classified its marketable investment securities as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at December 31, 2017 and June 30, 2017 were as follows: Gross Gross unrealized unrealized Amortized holding holding Estimated cost gains losses fair value At December 31, 2017: Cash and cash equivalents: Cash $ 85.9 $ — $ — $ 85.9 Cash equivalents 2.8 — — $ 2.8 Total cash and cash equivalents 88.7 — — 88.7 Available-for-sale: Corporate bonds and notes 57.9 — (0.2 ) 57.7 Municipal bonds 34.9 — (0.1 ) 34.8 Federal agency issues 12.6 — (0.1 ) 12.5 US government securities 8.3 — — 8.3 Total $ 202.4 $ — $ (0.4 ) $ 202.0 Gross Gross unrealized unrealized Amortized holding holding Estimated cost gains losses fair value At June 30, 2017: Cash and cash equivalents: Cash $ 83.5 $ — $ — $ 83.5 Cash equivalents 18.9 — — 18.9 Total cash and cash equivalents 102.4 — — 102.4 Available-for-sale: Corporate bonds and notes 45.4 0.1 (0.1 ) 45.4 Municipal bonds 32.7 — — 32.7 Federal agency issues 11.6 — (0.1 ) 11.5 US government securities 7.2 — — 7.2 Total $ 199.3 $ 0.1 $ (0.2 ) $ 199.2 Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities are as follows at December 31, 2017: Amortized Estimated cost fair value Cash $ 85.9 $ 85.9 Cash equivalents 2.8 2.8 Available-for-sale: Due within one year 54.9 54.8 Due after one year through five years 58.8 58.5 Due after five years — — Total $ 202.4 $ 202.0

Property, Plant and Equipment,

Property, Plant and Equipment, Net	6 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Property, Plant and Equipment, Net	(4) PROPERTY, PLANT AND EQUIPMENT, NET December 31, June 30, 2017 2017 Land $ 2.5 $ 2.3 Buildings and improvements 19.8 17.1 Leasehold improvements 22.6 22.1 Equipment 109.9 106.9 154.8 148.4 Less accumulated depreciation (106.4 ) (97.3 ) Property, plant and equipment, net $ 48.4 $ 51.1 Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Depreciation expense $ 3.8 $ 3.6 $ 7.7 $ 7.3

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Dec. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	(5) GOODWILL AND INTANGIBLE ASSETS Goodwill The Company has recorded goodwill of $319.4 from the acquisitions of Assurex that was completed on August 31, 2016, Sividon Diagnostics GmbH (“Sividon”) that was completed on May 31, 2016, Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the “Clinic”) that was completed on February 27, 2015, Crescendo Bioscience, Inc. that was completed on February 28, 2014 and Rules-Based Medicine, Inc. that was completed on May 31, 2011. Of this goodwill, $253.3 relates to the Company’s diagnostic segment and $66.1 relates to the other segment. The following summarizes changes to the goodwill balance for the six months ended December 31, 2017: Carrying amount Beginning balance July 1, 2017 $ 316.1 Adjustments to acquisitions (see note 2) 1.9 Translation adjustments 1.4 Ending balance December 31, 2017 $ 319.4 Intangible Assets Intangible assets primarily consist of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as non-amortizable intangible assets of in-process technologies and research and development. The following summarizes the amounts reported as intangible assets: Gross Carrying Accumulated Amount Amortization Net At December 31, 2017: Purchased licenses and technologies $ 527.2 $ (79.6 ) $ 447.6 Customer relationships 4.6 (3.1 ) 1.5 Trademarks 3.0 (0.9 ) 2.1 Total amortized intangible assets 534.8 (83.6 ) 451.2 In-process research and development 24.0 — 24.0 Total unamortized intangible assets 24.0 — 24.0 Total intangible assets $ 558.8 $ (83.6 ) $ 475.2 Gross Carrying Accumulated Amount Amortization Net At June 30, 2017: Purchased licenses and technologies $ 525.7 $ (61.2 ) $ 464.5 Customer relationships 4.6 (2.8 ) 1.8 Trademarks 3.0 (0.8 ) 2.2 Total amortized intangible assets 533.3 (64.8 ) 468.5 In-process research and development 23.1 — 23.1 Total unamortized intangible assets 23.1 — 23.1 Total intangible assets $ 556.4 $ (64.8 ) $ 491.6 The Company recorded amortization expense during the respective periods for these intangible assets as follows: Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Amortization of intangible assets $ 9.3 $ 9.3 $ 18.6 $ 14.8

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Dec. 31, 2017
Payables And Accruals [Abstract]
Accrued Liabilities	(6) ACCRUED LIABILITIES December 31, June 30, 2017 2017 Employee compensation and benefits $ 42.0 $ 44.4 Accrued taxes payable 3.2 7.1 Other 15.6 14.1 Total accrued liabilities $ 60.8 $ 65.6

Long-Term Debt

Long-Term Debt	6 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Long-Term Debt	(7) LONG-TERM DEBT On December 23, 2016, the Company entered into a senior secured revolving credit facility (the “Facility”) by and among Myriad, as borrower, the lenders from time to time party thereto, providing for the Facility in an aggregate principal amount of up to $300.0, which amount shall include $10.0 sublimits, in each case, for swingline loans and letters of credit. Pursuant to the Facility, Myriad borrowed revolving loans in an aggregate principal amount of $205.0 with $0.7 upfront fees and $0.3 debt issuance costs recorded as a debt discount to be amortized over the term of the Facility resulting in current net long-term debt of $204.0. The Facility matures on December 23, 2021. There are no scheduled principal payments of the Facility prior to its maturity date. The proceeds of the Facility were used (i) to refinance in full the obligations under the Term Loan, (ii) to pay any fees and expenses related thereto, and (iii) for working capital and general corporate purposes. The Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Credit Agreement also contains certain customary events of default. Covenants in the Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company’s ability to incur additional indebtedness, create certain types of liens, mergers or consolidations, and/or change in control transactions. The Facility may also prohibit or place limitations on the Company’s ability to sell assets, pay dividends or provide other distributions to shareholders. The Company must maintain a specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Facility. We were in compliance with all financial covenants at December 31, 2017. During the three and six months ended December 31, 2017, the Company made $31.0 and $56.0 in principal repayments respectively. The Facility is secured by a first-lien security interest in substantially all of the assets of Myriad and certain of its domestic subsidiaries and each such domestic subsidiary of Myriad has guaranteed the repayment of the Facility. Amounts outstanding under the Facility were as follows: December 31, June 30, 2017 2017 Long-term debt $ 44.0 $ 100.0 Long-term debt discount (0.8 ) (0.9 ) Net long-term debt $ 43.2 $ 99.1

Other Long Term Liabilities

Other Long Term Liabilities	6 Months Ended
	Dec. 31, 2017
Other Liabilities Disclosure [Abstract]
Other Long Term Liabilities	(8) OTHER LONG TERM LIABILITIES December 31, June 30, 2017 2017 Pension obligation 6.3 5.9 Other 0.3 1.3 Total other long term liabilities $ 6.6 $ 7.2 The Company has two non-contributory defined benefit pension plans for certain Clinic employees. Participation in the plans excludes those employees hired after 2002. As of December 31, 2017 the fair value of the plan assets were approximately $0.1 resulting in a net pension liability of $6.3.

Preferred and Common Stockholde

Preferred and Common Stockholder's Equity	6 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Preferred and Common Stockholder's Equity	(9) PREFERRED AND COMMON STOCKHOLDER’S EQUITY The Company is authorized to issue up to 5.0 shares of preferred stock, par value $0.01 per share. There were no preferred shares outstanding at December 31, 2017. The Company is authorized to issue up to 150.0 shares of common stock, par value $0.01 per share. There were 69.4 shares issued and outstanding at December 31, 2017. Common shares issued and outstanding Six months ended December 31, 2017 2016 Common stock issued and outstanding at July 1 68.4 69.1 Common stock issued upon exercise of options and employee stock plans 1.0 0.6 Repurchase and retirement of common stock — (1.6 ) Common stock issued and outstanding at December 31 69.4 68.1 Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations: Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Denominator: Weighted-average shares outstanding used to compute basic EPS 69.3 68.2 68.9 68.5 Effect of dilutive shares 2.6 0.1 2.3 0.4 Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 71.9 68.3 71.2 68.9 Certain outstanding options and restricted stock units (“RSUs”) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows: Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Anti-dilutive options and RSU's excluded from EPS computation 0.2 8.7 0.5 6.4 Stock Repurchase Program In June 2016, the Company’s Board of Directors authorized an eighth share repurchase program of $200.0 of the Company’s outstanding common stock. The Company plans to repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company’s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. As of December 31, 2017, the Company has $160.7 remaining on its current share repurchase authorization. The Company uses the par value method of accounting for its stock repurchases. As a result of the stock repurchases, the Company reduced common stock and additional paid-in capital and recorded charges to accumulated deficit. The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to accumulated deficit for the repurchases for periods ended December 31, 2017 and 2016 were as follows: Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Shares purchased and retired — 0.6 — 1.6 Common stock and additional paid-in-capital reductions $ — $ 5.4 $ — $ 14.5 Charges to retained earnings $ — $ 4.8 $ — $ 17.1

Income Taxes

Income Taxes	6 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	(10) INCOME TAXES On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was enacted. The Tax Act makes broad and complex changes to the U.S. tax code that will affect our fiscal year ending June 30, 2018, including, but not limited to (1) reducing the U.S. federal corporate tax rate from 35 percent to 21 percent; (2) requiring companies to pay a one-time transition tax on certain unrepatriated earnings of foreign subsidiaries; (3) generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries; (4) requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (5) creating the base erosion anti-abuse tax (BEAT), a new minimum tax; (6) creating a new limitation on deductible interest expense; (7) revising the rules that limit the deductibility of compensation to certain highly compensated executives, and (8) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017. The SEC staff issued SAB 118, which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the Tax Act. In connection with our initial analysis of the impact of the Tax Act and consistent with the requirement to record a provisional estimate when applicable, the Company recorded a discrete net income tax benefit during the quarter ended December 31, 2017 of approximately $32.6. This provisional estimate primarily consists of a net benefit for the corporate rate reduction due to the revaluing of its net deferred tax liabilities as a result of the reduction in the federal corporate tax rates. The Company’s net deferred tax liabilities represent temporary differences between the book bases of assets which are greater than their tax bases. Upon the reversal of those temporary differences, the future tax impact will be based on the lower federal corporate tax rate enacted by the Tax Act. The Company is continuing to gather information and to analyze aspects of the Tax Act, which could potentially affect the estimated impact on the deferred tax balances. For various reasons that are discussed more fully below, we have not completed our accounting for the income tax effects of certain elements of the Tax Act. To the extent we were not yet able to make reasonable estimates of the impact of certain elements, we have not recorded any adjustments related to those elements and have continued accounting for them in accordance with ASC 740 on the basis of the tax laws in effect before the Tax Act. In addition to the discrete benefit recorded during the quarter ended December 31, 2017 for the provisional estimated impact on the Company’s net deferred tax liabilities, the lower federal corporate tax rate reduced the Company’s estimated annual effective tax rate which was applied to year to date operating results in accordance with the interim accounting guidelines. The Company estimates that the reduction in the federal corporate rate will have an ongoing effect to reduce the Company’s income tax expense from continuing operations. As a result of changes made by the Tax Act, Section 162(m) will limit the deduction of compensation, including performance-based compensation, in excess of $1 million paid to anyone who, for tax years beginning after January 1, 2018, serves as the Chief Executive Officer or Chief Financial Officer, or who is among the three most highly compensated executive officers for any fiscal year. The only exception to this rule is for compensation that is paid pursuant to a binding written contract in effect on November 2, 2017 that would have otherwise been deductible under the prior Section 162(m) rules. Accordingly, any compensation paid in the future pursuant to new compensation arrangements entered into after November 2, 2017, even if performance-based, will count towards the $1 million fiscal year deduction limit if paid to a covered executive. The Company estimates that there will not be a material impact during the current quarter or fiscal year, as the law is effective for tax years beginning after January 1, 2018. The Company has evaluated its binding contracts entered into prior to November 2, 2017, and believes there will be no material impact for adjustments related to deferred equity compensation currently carried as a deferred tax asset on the Company’s balance sheet. The Company is still analyzing certain aspects of the Act and refining calculations, which could potentially affect the impact of this provision. The Tax Act also implements certain changes on the taxation of the Company’s foreign operations. Our accounting for the following elements of the Tax Act is incomplete, and we were not yet able to make reasonable estimates of the effects. Therefore, no provisional adjustments were recorded. The Deemed Repatriation Transition Tax (Transition Tax) is a tax on previously untaxed accumulated and current earnings and profits (E&P) of certain of our foreign subsidiaries. To determine the amount of the Transition Tax, we must determine, in addition to other factors, the amount of post-1986 E&P of the relevant subsidiaries, as well as the amount of non-U.S. income taxes paid on such earnings. While the Company estimates that there will not be a material impact during the current quarter or current fiscal year due to the Transition Tax, we are not able to make a reasonable estimate of the Transition Tax and have not recorded a provisional amount. We are continuing to gather additional information needed to finalize the amount of post-1986 E&P to more precisely compute the amount of the Transition Tax. The Tax Act creates a new requirement that certain income (i.e., GILTI) earned by controlled foreign corporations (CFCs) must be included currently in the gross income of the CFCs’ U.S. shareholder. Global intangible low-taxed income (GILTI) is the excess of the shareholder’s “net CFC tested income” over the net deemed tangible income return, which is currently defined as the excess of (1) 10 percent of the aggregate of the U.S. shareholder’s pro rata share of the qualified business asset investment of each CFC with respect to which it is a U.S. shareholder over (2) the amount of certain interest expense taken into account in the determination of net CFC-tested income. Because of the complexity of the new GILTI tax rules, we are continuing to evaluate this provision of the Tax Act and the application of ASC 740. Under U.S. GAAP, we are allowed to make an accounting policy choice of either (1) treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current-period expense when incurred (the “period cost method”) or (2) factoring such amounts into a company’s measurement of its deferred taxes (the “deferred method”). The Company is not making a policy election at this time. Our calculation of the deferred balance with respect to the new GILTI tax rules will depend, in part, on analyzing our global income to determine whether we expect to have future U.S. inclusions in taxable income related to GILTI and, if so, what the impact is expected to be. Because whether we expect to have future U.S. inclusions in taxable income related to GILTI depends on not only our current structure and estimated future results of global operations but also our intent and ability to modify our structure and/or our business, we are not yet able to reasonably estimate the effect of this provision of the Tax Act. Therefore, we have not made any adjustments related to potential GILTI tax in our financial statements. Other revisions to the taxation of foreign earnings will not be effective until the Company’s fiscal year ending on June 30, 2019. The Company is in the process of evaluating the additional provisions of the Tax Act that will become effective in their fiscal year ending June 30, 2019. The impact of the Tax Act may differ from these estimates, possibly materially, due to, among other things, changes in interpretations and assumptions the Company has made, guidance that may be issued and actions the Company may take as a result of the Tax Act. The Company will continue to update the provisional estimates as information is obtained, such as state impacts regarding decoupling from the Tax Act provisions, realization of deferred amounts in the fiscal year, and accounting method elections that may be made by the Company. In order to determine the Company’s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates. The Tax Act reduces the federal corporate tax rate to 21% in the fiscal year ending June 30, 2018. Section 15 of the Internal Revenue Code Stipulates that our fiscal year ending June 30, 2018, will have a blended corporate tax rate of 28 percent, which is based on the applicable tax rates before and after the Tax Act and the number of days in the year. Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter. Income tax expense (benefit) for the three months ended December 31, 2017 was $(28.4), which included a provisional one-time benefit of $32.6 related to the Tax Act. After excluding the one-time benefit related to the Tax Act, the income tax expense for the three months ended December 31, 2017 was $4.2, or approximately 113.5% of pre-tax income compared to $6.2, or approximately 51.2%% of pre-tax income, for the three months ended December 31, 2016. Income tax expense for the six months ended December 31, 2017 (after excluding the one-time Tax Act benefit of $32.6) was $9.8, or approximately 10.7% of pre-tax income compared to $11.4, or approximately 70.8% of pre-tax income, for the six months ended December 31, 2016. Income tax expense for the three and six months ended December 31, 2017 is based on the Company’s estimated annual effective tax rate for the full fiscal year ending June 30, 2018, adjusted by discrete items recognized during the period. For the three and six months ended December 31, 2017, the Company’s recognized effective tax rate differs from the U.S. federal statutory rate primarily due to the effect of fair value adjustments related to acquisition contingent consideration, state income taxes, the prior year adoption of ASU 2016-09 (“ASU 2016-09”), Improvements to Employee Share-Based Payment Accounting and other benefits realized from the differences related to the earlier recognition of the tax effect of equity compensation expense from incentive stock options and the deduction realized when those options are disqualified upon exercise and sale. The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations. The Company is currently under audit by the IRS for the fiscal years ended June 30, 2014 and June 30, 2015; the State of New Jersey for the fiscal years June 30, 2007 through 2013; and Canada for the fiscal years June 30, 2014 through 2015. Annual and interim tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	(11) SHARE-BASED COMPENSATION On November 30, 2017, the shareholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (the “2017 Plan”). The 2017 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of restricted and unrestricted stock awards to employees, consultants and directors. The plan allows for issuance of up to 1.4 shares of common stock. In addition, as of December 31, 2017, the Company may grant additional shares of common stock under the 2017 plan up to 1.7 options outstanding under our 2003 Plan and 6.8 options and restricted stock units outstanding under our 2010 Plan, that expire or are cancelled without delivery of shares of common stock. The number of shares, terms, and vesting periods are determined by the Company’s Board of Directors or a committee thereof on an option-by-option basis. Options generally vest ratably over service periods of four years. Options granted after December 5, 2012 expire eight years from the date of grant, and options granted prior to that date generally expire ten years from the date of grant. In September 2014, the Company began issuing restricted stock units (“RSUs”) in lieu of stock options. RSUs granted to employees generally vest ratably over four years on the anniversary date of the last day of the month in which the RSUs are granted. The number of RSUs awarded to certain executive officers may be reduced if certain additional performance metrics are not met. Options and RSUs granted to our non-employee directors vest in full upon completion of one year of service on the Board following the date of the grant. Stock Options A summary of the stock option activity under the Company’s plans for the six months ended December 31, 2017 is as follows: Number of shares Weighted average exercise price Options outstanding at June 30, 2017 8.0 $ 24.67 Options granted — $ — Less: Options exercised (0.5 ) $ 23.39 Options canceled or expired (0.1 ) $ 26.60 Options outstanding at December 31, 2017 7.4 $ 24.75 Options exercisable at December 31, 2017 7.4 $ 24.75 As of December 31, 2017, there was no unrecognized share-based compensation expense related to stock options. Restricted Stock Units A summary of the RSU activity under the Company’s plans for the six months ended December 31, 2017 is as follows: Number of shares Weighted average grant date fair value RSUs outstanding at June 30, 2017 2.0 $ 33.02 RSUs granted 1.1 $ 32.64 Less: RSUs vested (0.7 ) $ 34.97 RSUs canceled (0.1 ) $ 27.40 RSUs outstanding at December 31, 2017 2.3 $ 32.77 As of December 31, 2017, there was $46.7 of total unrecognized share-based compensation expense related to RSUs that will be recognized over a weighted-average period of 2.4 years. This unrecognized compensation expense is equal to the fair value of RSUs expected to vest. Employee Stock Purchase Plan The Company also has an Employee Stock Purchase Plan that was approved by shareholders in 2012 (the “2012 Purchase Plan”), under which 2.0 shares of common stock have been authorized. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. As of December 31, 2017, approximately 0.7 shares of common stock have been issued under the 2012 Purchase Plan. Share-Based Compensation Expense Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows: Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Cost of molecular diagnostic testing $ 0.2 $ 0.3 $ 0.3 $ 0.4 Cost of pharmaceutical and clinical services 0.0 0.0 0.1 0.1 Research and development expense 1.2 1.4 2.1 3.0 Selling, general, and administrative expense 5.5 5.7 10.8 11.7 Total share-based compensation expense $ 6.9 $ 7.4 $ 13.3 $ 15.2

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	(12) FAIR VALUE MEASUREMENTS The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value of contingent consideration related to the Sividon and Assurex acquisitions as well as the long-term debt were categorized as a level 3 liability, as the measurement amount is based primarily on significant inputs not observable in the market. For more information about the Assurex acquisition, see Note 2 "Acquisitions". The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels: Level 1— quoted prices in active markets for identical assets and liabilities. Level 2— observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities. Level 3— unobservable inputs. All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, we reassess the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected earn out liability. This fair value measurement is considered a Level 3 measurement because we estimate projections during the earn out period utilizing various potential pay-out scenarios. Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn out itself, the related projections, and the overall business. The contingent earn out liabilities are classified as a component of long-term and short-term contingent consideration in our consolidated balance sheets. Changes to these estimated liabilities are reflected in change in the fair value of contingent consideration in our consolidated income statement. The fair value of our long-term debt, which we consider a Level 3 measurement, is estimated using discounted cash flow analyses, based on the Company’s current estimated incremental borrowing rates for similar borrowing arrangements. The fair value of long-term debt is estimated to be $38.7 at December 31, 2017. The following table sets forth the fair value of the financial assets that the Company re-measures on a regular basis: Level 1 Level 2 Level 3 Total December 31, 2017 Money market funds (a) $ 2.8 $ — $ — $ 2.8 Corporate bonds and notes — 57.7 — 57.7 Municipal bonds — 34.8 — 34.8 Federal agency issues — 12.5 — 12.5 US government securities — 8.3 — 8.3 Contingent consideration — — (81.0 ) (81.0 ) Total $ 2.8 $ 113.3 $ (81.0 ) $ 35.1 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest Level 1 Level 2 Level 3 Total June 30, 2017 Money market funds (a) $ 7.4 $ — $ — $ 7.4 Corporate bonds and notes — 50.4 — 50.4 Municipal bonds — 36.9 — 36.9 Federal agency issues — 13.8 — 13.8 US government securities — 7.2 — 7.2 Contingent consideration — — (140.5 ) (140.5 ) Total $ 7.4 $ 108.3 $ (140.5 ) $ (24.8 ) (a) Money market funds are primarily comprised of exchange traded funds and accrued interest The following table reconciles the change in the fair value of the contingent consideration during the periods presented: Carrying amount Balance June 30, 2017 $ 140.5 Change in fair value recognized in the income statement (60.2 ) Translation adjustments recognized in other comprehensive income 0.7 Ending balance December 31, 2017 $ 81.0

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(13) COMMITMENTS AND CONTINGENCIES The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. As of December 31, 2017, the management of the Company believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results, or cash flows.

Employee Deferred Savings Plan

Employee Deferred Savings Plan	6 Months Ended
	Dec. 31, 2017
Postemployment Benefits [Abstract]
Employee Deferred Savings Plan	(14) EMPLOYEE DEFERRED SAVINGS PLAN The Company has a deferred savings plan which qualifies under Section 401(k) of the Internal Revenue Code. Substantially all of the Company’s U.S. employees are covered by the plan. The Company makes matching contributions of 50% of each employee’s contribution with the employer’s contribution not to exceed 4% of the employee’s compensation. The Company recorded contributions to the plan as follows: Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Deferred savings plan contributions $ 1.6 $ 1.4 $ 3.5 $ 3.0

Segment and Related Information

Segment and Related Information	6 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Segment and Related Information	(15) SEGMENT AND RELATED INFORMATION The Company’s business is aligned with how the Chief Operating Decision Maker reviews performance and makes decisions in managing the Company. The business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. Segment revenue and operating income (loss) were as follows during the periods presented: Diagnostics Other Total Three months ended December 31, 2017 Revenues $ 179.2 $ 14.8 $ 194.0 Depreciation and amortization 11.7 1.4 13.1 Segment operating income (loss) 34.6 (30.2 ) 4.4 Three months ended December 31, 2016 Revenues $ 183.9 $ 12.6 $ 196.5 Depreciation and amortization 11.5 1.4 12.9 Segment operating income (loss) 32.1 (15.1 ) 17.0 Six months ended December 31, 2017 Revenues $ 358.0 $ 26.2 $ 384.2 Depreciation and amortization 23.5 2.8 26.3 Segment operating income (loss) 68.6 23.3 91.9 Six months ended December 31, 2016 Revenues $ 348.9 $ 25.0 $ 373.9 Depreciation and amortization 19.3 2.8 22.1 Segment operating income (loss) 62.0 (39.4 ) 22.6 Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Total operating income for reportable segments $ 4.4 $ 17.0 $ 91.9 $ 22.6 Unallocated amounts: Interest income 0.4 0.3 0.8 0.6 Interest expense (0.7 ) (2.6 ) (1.7 ) (3.3 ) Other (0.4 ) (2.6 ) (0.7 ) (3.8 ) Income from operations before income taxes 3.7 12.1 90.3 16.1 Income tax provision (28.4 ) 6.2 (22.8 ) 11.4 Net income 32.1 5.9 113.1 4.7 Net loss attributable to non-controlling interest — — (0.1 ) — Net income attributable to Myriad Genetics, Inc. stockholders $ 32.1 $ 5.9 $ 113.2 $ 4.7

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	6 Months Ended
	Dec. 31, 2017
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	(16) SUPPLEMENTAL CASH FLOW INFORMATION Six months ended December 31, 2017 2016 Cash paid during the period for income taxes $ 5.5 $ 8.0 Non-cash investing and financing activities: Fair value adjustment on marketable investment securities recorded to other stockholder's equity (0.3 ) (0.8 )

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the “Company” or “Myriad”) in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The condensed consolidated financial statements herein should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2017, included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017. Operating results for the three and six months ended December 31, 2017 may not necessarily be indicative of results to be expected for any other interim period or for the full year. The consolidated financial statements include the accounts of the Company’s majority-owned subsidiary, Assurex Canada, Ltd. which is 85% owned by Assurex Health, Inc. (“Assurex”), a wholly owned subsidiary of the Company, and 15% owned by the Centre for Addiction and Mental Health. Assurex Canada, Ltd. is a consolidated subsidiary of Assurex Health, Inc. The value of the non-controlling interest represents the portion of Assurex Canada, Ltd.’s profit or loss and net assets that is not held by Assurex Health, Inc. The Company attributes comprehensive income or loss of the subsidiary between the Company and the non-controlling interest based on the respective ownership interest. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
New Accounting Pronouncements	New Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective beginning in the first quarter of fiscal 2020. Early adoption of ASU 2016-02 is permitted. ASU 2016-02 requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company’s management is currently evaluating the impact of adopting ASU 2016-02 on the Company’s consolidated financial statements. In May 2014, the FASB issued the converged standard on revenue recognition with the objective of providing a single, comprehensive model for all contracts with customers to improve comparability in the financial statements of companies reporting using International Financial Reporting Standards and U.S. GAAP. The standard contains principles that an entity must apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity must recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. An entity can apply the revenue standard retrospectively to each prior reporting period presented (full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings (modified retrospective method). The standard will be effective for the Company first quarter of fiscal 2019, with early adoption permitted for annual periods beginning after December 16, 2016. The Company plans to adopt the standard July 1, 2018 using the full retrospective method. The Company continues to assess the impact of this standard on its results of operations, financial position and cash flows. Based on its preliminary assessment, the Company expects the majority of the amounts that have historically been classified as bad debt expense, primarily related to patient responsibility, will be reflected as a reduction of the transaction price and therefore as a reduction in revenue. The Company anticipates an increase in the level of required financial statement disclosures due to the standard.

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Dec. 31, 2017
Changes in Carrying Amount of Goodwill	The following summarizes changes to the goodwill balance for the six months ended December 31, 2017 Carrying amount Beginning balance July 1, 2017 $ 316.1 Adjustments to acquisitions (see note 2) 1.9 Translation adjustments 1.4 Ending balance December 31, 2017 $ 319.4
Pro Forma Results of Acquisitions	Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operation of the combined company would have been if the acquisition had occurred at the beginning of the period presented nor are they indicative of future results of operations and are not necessarily indicative of results that might have been achieved had the acquisition been consummated as of July 1, 2016. Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Revenue $ 194.0 $ 196.5 $ 384.2 $ 385.4 Income from operations 4.4 13.2 91.9 12.4 Net income (loss) 32.1 5.9 113.2 (13.3 ) Net income (loss) per share, basic $ 0.46 $ 0.09 $ 1.64 $ (0.19 ) Net income (loss) per share, diluted $ 0.45 $ 0.09 $ 1.59 $ (0.19 )
Assurex [Member]
Allocation of Consideration Transferred	The final purchase price allocation is as follows: Estimated Fair Value Current assets $ 18.2 Intangible assets 295.6 Equipment 1.9 Goodwill 121.1 Current liabilities (18.9 ) Deferred tax liability (66.3 ) Total fair value purchase price $ 351.6 Less: Contingent consideration (130.0 ) Less: Cash acquired (5.5 ) Total cash consideration transferred $ 216.1
Changes in Carrying Amount of Goodwill	Change in goodwill for the period ended December 31, 2017 is shown below: Carrying amount Balance June 30, 2017 $ 119.2 Fair value adjustment to equipment (0.1 ) Non-controlling interest adjustment 0.2 Change in deferred tax liability 1.8 Ending balance December 31, 2017 $ 121.1

Marketable Investment Securit25

Marketable Investment Securities (Tables)	6 Months Ended
	Dec. 31, 2017
Investments Debt And Equity Securities [Abstract]
Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security	The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at December 31, 2017 and June 30, 2017 were as follows: Gross Gross unrealized unrealized Amortized holding holding Estimated cost gains losses fair value At December 31, 2017: Cash and cash equivalents: Cash $ 85.9 $ — $ — $ 85.9 Cash equivalents 2.8 — — $ 2.8 Total cash and cash equivalents 88.7 — — 88.7 Available-for-sale: Corporate bonds and notes 57.9 — (0.2 ) 57.7 Municipal bonds 34.9 — (0.1 ) 34.8 Federal agency issues 12.6 — (0.1 ) 12.5 US government securities 8.3 — — 8.3 Total $ 202.4 $ — $ (0.4 ) $ 202.0 Gross Gross unrealized unrealized Amortized holding holding Estimated cost gains losses fair value At June 30, 2017: Cash and cash equivalents: Cash $ 83.5 $ — $ — $ 83.5 Cash equivalents 18.9 — — 18.9 Total cash and cash equivalents 102.4 — — 102.4 Available-for-sale: Corporate bonds and notes 45.4 0.1 (0.1 ) 45.4 Municipal bonds 32.7 — — 32.7 Federal agency issues 11.6 — (0.1 ) 11.5 US government securities 7.2 — — 7.2 Total $ 199.3 $ 0.1 $ (0.2 ) $ 199.2
Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale Securities	Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities are as follows at December 31, 2017: Amortized Estimated cost fair value Cash $ 85.9 $ 85.9 Cash equivalents 2.8 2.8 Available-for-sale: Due within one year 54.9 54.8 Due after one year through five years 58.8 58.5 Due after five years — — Total $ 202.4 $ 202.0

Property, Plant and Equipment26

Property, Plant and Equipment, Net (Tables)	6 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	December 31, June 30, 2017 2017 Land $ 2.5 $ 2.3 Buildings and improvements 19.8 17.1 Leasehold improvements 22.6 22.1 Equipment 109.9 106.9 154.8 148.4 Less accumulated depreciation (106.4 ) (97.3 ) Property, plant and equipment, net $ 48.4 $ 51.1 Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Depreciation expense $ 3.8 $ 3.6 $ 7.7 $ 7.3

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Dec. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The following summarizes changes to the goodwill balance for the six months ended December 31, 2017 Carrying amount Beginning balance July 1, 2017 $ 316.1 Adjustments to acquisitions (see note 2) 1.9 Translation adjustments 1.4 Ending balance December 31, 2017 $ 319.4
Summarized Amounts Reported as Intangible Assets	The following summarizes the amounts reported as intangible assets Gross Carrying Accumulated Amount Amortization Net At December 31, 2017: Purchased licenses and technologies $ 527.2 $ (79.6 ) $ 447.6 Customer relationships 4.6 (3.1 ) 1.5 Trademarks 3.0 (0.9 ) 2.1 Total amortized intangible assets 534.8 (83.6 ) 451.2 In-process research and development 24.0 — 24.0 Total unamortized intangible assets 24.0 — 24.0 Total intangible assets $ 558.8 $ (83.6 ) $ 475.2 Gross Carrying Accumulated Amount Amortization Net At June 30, 2017: Purchased licenses and technologies $ 525.7 $ (61.2 ) $ 464.5 Customer relationships 4.6 (2.8 ) 1.8 Trademarks 3.0 (0.8 ) 2.2 Total amortized intangible assets 533.3 (64.8 ) 468.5 In-process research and development 23.1 — 23.1 Total unamortized intangible assets 23.1 — 23.1 Total intangible assets $ 556.4 $ (64.8 ) $ 491.6
Amortization for Intangible Assets	The Company recorded amortization expense during the respective periods for these intangible assets as follows: Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Amortization of intangible assets $ 9.3 $ 9.3 $ 18.6 $ 14.8

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Dec. 31, 2017
Payables And Accruals [Abstract]
Summary of Accrued Liabilities	December 31, June 30, 2017 2017 Employee compensation and benefits $ 42.0 $ 44.4 Accrued taxes payable 3.2 7.1 Other 15.6 14.1 Total accrued liabilities $ 60.8 $ 65.6

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	Amounts outstanding under the Facility were as follows: December 31, June 30, 2017 2017 Long-term debt $ 44.0 $ 100.0 Long-term debt discount (0.8 ) (0.9 ) Net long-term debt $ 43.2 $ 99.1

Other Long Term Liabilities (Ta

Other Long Term Liabilities (Tables)	6 Months Ended
	Dec. 31, 2017
Other Liabilities Disclosure [Abstract]
Summary of Other Long Term Liabilities	December 31, June 30, 2017 2017 Pension obligation 6.3 5.9 Other 0.3 1.3 Total other long term liabilities $ 6.6 $ 7.2

Preferred and Common Stockhol31

Preferred and Common Stockholder's Equity (Tables)	6 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Summary of Common Shares Issued and Outstanding	Common shares issued and outstanding Six months ended December 31, 2017 2016 Common stock issued and outstanding at July 1 68.4 69.1 Common stock issued upon exercise of options and employee stock plans 1.0 0.6 Repurchase and retirement of common stock — (1.6 ) Common stock issued and outstanding at December 31 69.4 68.1
Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations	The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations: Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Denominator: Weighted-average shares outstanding used to compute basic EPS 69.3 68.2 68.9 68.5 Effect of dilutive shares 2.6 0.1 2.3 0.4 Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 71.9 68.3 71.2 68.9
Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation	These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows: Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Anti-dilutive options and RSU's excluded from EPS computation 0.2 8.7 0.5 6.4
Schedule of Stock Repurchases	The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to accumulated deficit for the repurchases for periods ended December 31, 2017 and 2016 were as follows: Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Shares purchased and retired — 0.6 — 1.6 Common stock and additional paid-in-capital reductions $ — $ 5.4 $ — $ 14.5 Charges to retained earnings $ — $ 4.8 $ — $ 17.1

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding	A summary of the stock option activity under the Company’s plans for the six months ended December 31, 2017 is as follows: Number of shares Weighted average exercise price Options outstanding at June 30, 2017 8.0 $ 24.67 Options granted — $ — Less: Options exercised (0.5 ) $ 23.39 Options canceled or expired (0.1 ) $ 26.60 Options outstanding at December 31, 2017 7.4 $ 24.75 Options exercisable at December 31, 2017 7.4 $ 24.75
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding	A summary of the RSU activity under the Company’s plans for the six months ended December 31, 2017 is as follows: Number of shares Weighted average grant date fair value RSUs outstanding at June 30, 2017 2.0 $ 33.02 RSUs granted 1.1 $ 32.64 Less: RSUs vested (0.7 ) $ 34.97 RSUs canceled (0.1 ) $ 27.40 RSUs outstanding at December 31, 2017 2.3 $ 32.77
Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations	Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows: Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Cost of molecular diagnostic testing $ 0.2 $ 0.3 $ 0.3 $ 0.4 Cost of pharmaceutical and clinical services 0.0 0.0 0.1 0.1 Research and development expense 1.2 1.4 2.1 3.0 Selling, general, and administrative expense 5.5 5.7 10.8 11.7 Total share-based compensation expense $ 6.9 $ 7.4 $ 13.3 $ 15.2

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Assets	The following table sets forth the fair value of the financial assets that the Company re-measures on a regular basis: Level 1 Level 2 Level 3 Total December 31, 2017 Money market funds (a) $ 2.8 $ — $ — $ 2.8 Corporate bonds and notes — 57.7 — 57.7 Municipal bonds — 34.8 — 34.8 Federal agency issues — 12.5 — 12.5 US government securities — 8.3 — 8.3 Contingent consideration — — (81.0 ) (81.0 ) Total $ 2.8 $ 113.3 $ (81.0 ) $ 35.1 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest Level 1 Level 2 Level 3 Total June 30, 2017 Money market funds (a) $ 7.4 $ — $ — $ 7.4 Corporate bonds and notes — 50.4 — 50.4 Municipal bonds — 36.9 — 36.9 Federal agency issues — 13.8 — 13.8 US government securities — 7.2 — 7.2 Contingent consideration — — (140.5 ) (140.5 ) Total $ 7.4 $ 108.3 $ (140.5 ) $ (24.8 ) (a) Money market funds are primarily comprised of exchange traded funds and accrued interest
Change in Fair Value of Contingent Consideration	The following table reconciles the change in the fair value of the contingent consideration during the periods presented: Carrying amount Balance June 30, 2017 $ 140.5 Change in fair value recognized in the income statement (60.2 ) Translation adjustments recognized in other comprehensive income 0.7 Ending balance December 31, 2017 $ 81.0

Employee Deferred Savings Plan

Employee Deferred Savings Plan (Tables)	6 Months Ended
	Dec. 31, 2017
Postemployment Benefits [Abstract]
Recorded Contributions to Employee Deferred Savings Plan	The Company recorded contributions to the plan as follows: Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Deferred savings plan contributions $ 1.6 $ 1.4 $ 3.5 $ 3.0

Segment and Related Informati35

Segment and Related Information (Tables)	6 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Schedule of Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense	Segment revenue and operating income (loss) were as follows during the periods presented: Diagnostics Other Total Three months ended December 31, 2017 Revenues $ 179.2 $ 14.8 $ 194.0 Depreciation and amortization 11.7 1.4 13.1 Segment operating income (loss) 34.6 (30.2 ) 4.4 Three months ended December 31, 2016 Revenues $ 183.9 $ 12.6 $ 196.5 Depreciation and amortization 11.5 1.4 12.9 Segment operating income (loss) 32.1 (15.1 ) 17.0 Six months ended December 31, 2017 Revenues $ 358.0 $ 26.2 $ 384.2 Depreciation and amortization 23.5 2.8 26.3 Segment operating income (loss) 68.6 23.3 91.9 Six months ended December 31, 2016 Revenues $ 348.9 $ 25.0 $ 373.9 Depreciation and amortization 19.3 2.8 22.1 Segment operating income (loss) 62.0 (39.4 ) 22.6 Three months ended Six months ended December 31, December 31, 2017 2016 2017 2016 Total operating income for reportable segments $ 4.4 $ 17.0 $ 91.9 $ 22.6 Unallocated amounts: Interest income 0.4 0.3 0.8 0.6 Interest expense (0.7 ) (2.6 ) (1.7 ) (3.3 ) Other (0.4 ) (2.6 ) (0.7 ) (3.8 ) Income from operations before income taxes 3.7 12.1 90.3 16.1 Income tax provision (28.4 ) 6.2 (22.8 ) 11.4 Net income 32.1 5.9 113.1 4.7 Net loss attributable to non-controlling interest — — (0.1 ) — Net income attributable to Myriad Genetics, Inc. stockholders $ 32.1 $ 5.9 $ 113.2 $ 4.7

Supplemental Cash Flow Inform36

Supplemental Cash Flow Information (Tables)	6 Months Ended
	Dec. 31, 2017
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	Six months ended December 31, 2017 2016 Cash paid during the period for income taxes $ 5.5 $ 8.0 Non-cash investing and financing activities: Fair value adjustment on marketable investment securities recorded to other stockholder's equity (0.3 ) (0.8 )

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Total costs and expenses	$ 189.6	$ 179.5	$ 292.3	$ 351.3
Operating income (loss)	4.4	17	91.9	22.6
Total other income (expense)	$ (0.7)	(4.9)	$ (1.6)	(6.5)
Overstated [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Total costs and expenses		3.8		3.2
Understated [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Operating income (loss)		3.8		3.2
Total other income (expense)		$ 3.8		$ 3.2
Assurex [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Non controlling interest ownership percentage by parent	85.00%		85.00%
Centre For Addiction And Mental Health [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Non controlling interest ownership percentage by noncontrolling owners	15.00%		15.00%

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) $ in Millions	Aug. 31, 2016USD ($)Milestone	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Jun. 30, 2017USD ($)
Business Acquisition [Line Items]
Cash payment on acquisition					$ 216.1
Change in non-controlling interest				$ 1.9
Assurex [Member]
Business Acquisition [Line Items]
Date of acquisition agreement	Aug. 31, 2016
Total consideration transferred	$ 351.6		$ 351.6
Business acquisition, net cash acquired	5.5		5.5
Cash payment on acquisition	$ 216.1
Number of potential performance-based milestones | Milestone	2
Additional payments upon completion of performance based milestones	$ 185
Contingent consideration	130		130
Contingent consideration, valuation method				The fair value of the performance-based milestones was determined by using the Monte Carlo Method.
Amount of cash consideration deposited in escrow account	$ 19.1
Fair value increase to equipment			(0.1)	$ (0.1)
Change in non-controlling interest			0.2	0.2
Net increase to goodwill due to change in non-controlling interest			0.1
Increase in deferred tax liability due to differences in GAAP and tax purchase accounting			1.8	$ 1.8
Acquired intangible assets			$ 295.6
Estimated net cash flows, discount rate				16.00%
Acquisition costs						$ 5
Revenue contributed by acquired entity		$ 31.7		$ 60.5
Operating expenses related to acquired entity		29.2		58.9
Assurex [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Acquired intangible assets		256.5		$ 256.5
Intangible assets estimated useful lives				17 years
Assurex [Member] | Database [Member]
Business Acquisition [Line Items]
Acquired intangible assets		$ 39.1		$ 39.1
Intangible assets estimated useful lives				5 years

Acquisitions - Allocation of Co

Acquisitions - Allocation of Consideration Transferred (Detail) - USD ($) $ in Millions	Aug. 31, 2016	Dec. 31, 2016	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017
Business Acquisition [Line Items]
Goodwill			$ 319.4		$ 316.1
Total cash consideration transferred		$ 216.1
Assurex [Member]
Business Acquisition [Line Items]
Current assets				$ 18.2
Intangible assets				295.6
Equipment				1.9
Goodwill			$ 121.1	121.1	$ 119.2
Current liabilities				(18.9)
Deferred tax liability				(66.3)
Total fair value purchase price	$ 351.6			351.6
Less: Contingent consideration	(130)			(130)
Less: Cash acquired	(5.5)			$ (5.5)
Total cash consideration transferred	$ 216.1

Acquisitions - Changes in Carry

Acquisitions - Changes in Carrying Amount of Goodwill (Detail) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Sep. 30, 2017	Dec. 31, 2017
Goodwill [Line Items]
Beginning balance	$ 316.1	$ 316.1
Non-controlling interest adjustment		1.9
Ending balance		319.4
Assurex [Member]
Goodwill [Line Items]
Beginning balance	119.2	119.2
Fair value adjustment to equipment	(0.1)	(0.1)
Non-controlling interest adjustment	0.2	0.2
Change in deferred tax liability	1.8	1.8
Ending balance	$ 121.1	$ 121.1

Acquisitions - Pro Forma Result

Acquisitions - Pro Forma Results of Acquisitions (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Business Combinations [Abstract]
Revenue	$ 194	$ 196.5	$ 384.2	$ 385.4
Income from operations	4.4	13.2	91.9	12.4
Net income (loss)	$ 32.1	$ 5.9	$ 113.2	$ (13.3)
Net income (loss) per share, basic	$ 0.46	$ 0.09	$ 1.64	$ (0.19)
Net income (loss) per share, diluted	$ 0.45	$ 0.09	$ 1.59	$ (0.19)

Marketable Investment Securit42

Marketable Investment Securities - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	$ 88.7	$ 102.4	$ 108	$ 68.5
Available-for-sale, Amortized cost	202.4	199.3
Gross unrealized holding gains		0.1
Gross unrealized holding losses	(0.4)	(0.2)
Available-for-sale, Estimated fair value	202	199.2
Amortized cost	202.4	199.3
Estimated fair value	202	199.2
Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	85.9	83.5
Cash and cash equivalents, Estimated fair value	85.9	83.5
Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	2.8	18.9
Cash and cash equivalents, Estimated fair value	2.8	18.9
Total Cash and Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	88.7	102.4
Cash and cash equivalents, Estimated fair value	88.7	102.4
Corporate Bonds and Notes [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale, Amortized cost	57.9	45.4
Gross unrealized holding gains		0.1
Gross unrealized holding losses	(0.2)	(0.1)
Available-for-sale, Estimated fair value	57.7	45.4
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale, Amortized cost	34.9	32.7
Gross unrealized holding losses	(0.1)
Available-for-sale, Estimated fair value	34.8	32.7
Federal Agency Issues [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale, Amortized cost	12.6	11.6
Gross unrealized holding losses	(0.1)	(0.1)
Available-for-sale, Estimated fair value	12.5	11.5
US Government Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale, Amortized cost	8.3	7.2
Available-for-sale, Estimated fair value	$ 8.3	$ 7.2

Marketable Investment Securit43

Marketable Investment Securities - Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale Securities (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	$ 88.7	$ 102.4	$ 108	$ 68.5
Due within one year, Amortized cost	54.9
Due after one year through five years, Amortized cost	58.8
Due after five years, Amortized cost	0
Total, Amortized cost	202.4	199.3
Due within one year, Estimated fair value	54.8
Due after one year through five years, Estimated fair value	58.5
Due after five years, Estimated fair value	0
Total, Estimated fair value	202	199.2
Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	85.9	83.5
Cash equivalents, Estimated fair value	85.9	83.5
Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	2.8	18.9
Cash equivalents, Estimated fair value	$ 2.8	$ 18.9

Property, Plant and Equipment44

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Jun. 30, 2017
Property Plant And Equipment [Abstract]
Land	$ 2.5	$ 2.3
Buildings and improvements	19.8	17.1
Leasehold improvements	22.6	22.1
Equipment	109.9	106.9
Gross property, plant and equipment	154.8	148.4
Less accumulated depreciation	(106.4)	(97.3)
Property, plant and equipment, net	$ 48.4	$ 51.1

Property, Plant and Equipment45

Property, Plant and Equipment, Net - Schedule of Depreciation Expense (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Depreciation expense	$ 3.8	$ 3.6	$ 7.7	$ 7.3

Goodwill and Intangible Asset46

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Jun. 30, 2017
Goodwill And Intangible Assets [Line Items]
Goodwill	$ 319.4	$ 316.1
Diagnostics [Member]
Goodwill And Intangible Assets [Line Items]
Goodwill	253.3
Other [Member]
Goodwill And Intangible Assets [Line Items]
Goodwill	$ 66.1

Goodwill and Intangible Asset47

Goodwill and Intangible Assets - Summary of Changes to Goodwill Balance (Detail) $ in Millions	6 Months Ended
	Dec. 31, 2017USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Beginning balance	$ 316.1
Adjustments to acquisitions	1.9
Translation adjustments	1.4
Ending balance	$ 319.4

Goodwill and Intangible Asset48

Goodwill and Intangible Assets - Summarized Amounts Reported as Intangible Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Jun. 30, 2017
Intangible Assets [Line Items]
Gross Carrying Amount, amortized intangible assets	$ 534.8	$ 533.3
Gross Carrying Amount, total intangible assets	558.8	556.4
Accumulated Amortization	(83.6)	(64.8)
Net, amortized intangible assets	451.2	468.5
Net, total intangible assets	475.2	491.6
Net, non-amortizable intangible assets	24	23.1
In-Process Research and Development [Member]
Intangible Assets [Line Items]
Net, non-amortizable intangible assets	24	23.1
Purchased Licenses and Technologies [Member]
Intangible Assets [Line Items]
Gross Carrying Amount, amortized intangible assets	527.2	525.7
Accumulated Amortization	(79.6)	(61.2)
Net, amortized intangible assets	447.6	464.5
Customer Relationships [Member]
Intangible Assets [Line Items]
Gross Carrying Amount, amortized intangible assets	4.6	4.6
Accumulated Amortization	(3.1)	(2.8)
Net, amortized intangible assets	1.5	1.8
Trademarks [Member]
Intangible Assets [Line Items]
Gross Carrying Amount, amortized intangible assets	3	3
Accumulated Amortization	(0.9)	(0.8)
Net, amortized intangible assets	$ 2.1	$ 2.2

Goodwill and Intangible Asset49

Goodwill and Intangible Assets - Amortization on Intangible Assets (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 9.3	$ 9.3	$ 18.6	$ 14.8

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Jun. 30, 2017
Payables And Accruals [Abstract]
Employee compensation and benefits	$ 42	$ 44.4
Accrued taxes payable	3.2	7.1
Other	15.6	14.1
Total accrued liabilities	$ 60.8	$ 65.6

Long Term Debt - Additional Inf

Long Term Debt - Additional Information (Detail) - USD ($)	Dec. 23, 2016	Dec. 31, 2017	Dec. 31, 2017	Jun. 30, 2017
Debt Instrument [Line Items]
Long term debt, net		$ 43,200,000	$ 43,200,000	$ 99,100,000
Principal repayment			56,000,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Loans maximum borrowing capacity	$ 300,000,000
Aggregate principal amount of loan	205,000,000
Upfront fees	700,000
Debt issuance costs	300,000
Long term debt, net	$ 204,000,000
Maturity Date	Dec. 23, 2021
Scheduled principal payments prior to maturity date	$ 0
Principal repayment		$ 31,000,000	$ 56,000,000
Swingline Loans and Letters of Credit [Member]
Debt Instrument [Line Items]
Sublimits of loan	$ 10,000,000

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-Term Debt (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Jun. 30, 2017
Long-term Debt, Unclassified [Abstract]
Long-term debt	$ 44	$ 100
Long-term debt discount	(0.8)	(0.9)
Net long-term debt	$ 43.2	$ 99.1

Other Long Term Liabilities - S

Other Long Term Liabilities - Summary of Other Long Term Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Jun. 30, 2017
Other Liabilities Disclosure [Abstract]
Pension obligation	$ 6.3	$ 5.9
Other	0.3	1.3
Total other long term liabilities	$ 6.6	$ 7.2

Other Long Term Liabilities - A

Other Long Term Liabilities - Additional Information (Detail) $ in Millions	Dec. 31, 2017USD ($)plan	Jun. 30, 2017USD ($)
Other Liabilities Disclosure [Abstract]
Number of defined benefit pension plans | plan	2
Fair value of plan assets	$ 0.1
Net pension liability	$ 6.3	$ 5.9

Preferred and Common Stockhol55

Preferred and Common Stockholder's Equity - Additional Information (Detail) - USD ($)	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016
Class of Stock [Line Items]
Preferred stock, shares authorized	5,000,000
Preferred stock, par value	$ 0.01
Preferred stock, shares outstanding	0
Common stock, shares authorized	150,000,000
Common stock, par value	$ 0.01
Common stock, shares issued	69,400,000	68,400,000	68,100,000	69,100,000
Common stock, shares outstanding	69,400,000	68,400,000	68,100,000	69,100,000
Share repurchase program, remaining authorized repurchase amount	$ 160,700,000
Eighth Share Repurchase Program [Member]
Class of Stock [Line Items]
Share repurchase program, authorized amount				$ 200,000,000

Preferred and Common Stockhol56

Preferred and Common Stockholder's Equity - Summary of Common Shares Issued and Outstanding (Detail) - shares shares in Millions	6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Common stock issued, Beginning balance	68.4	69.1
Common stock outstanding, Beginning balance	68.4	69.1
Common stock issued upon exercise of options and employee stock plans	1	0.6
Repurchase and retirement of common stock		(1.6)
Common stock issued, Ending balance	69.4	68.1
Common stock outstanding, Ending balance	69.4	68.1

Preferred and Common Stockhol57

Preferred and Common Stockholder's Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Detail) - shares shares in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Weighted-average shares outstanding used to compute basic EPS	69.3	68.2	68.9	68.5
Effect of dilutive shares	2.6	0.1	2.3	0.4
Weighted-average shares outstanding and dilutive securities used to compute diluted EPS	71.9	68.3	71.2	68.9

Preferred and Common Stockhol58

Preferred and Common Stockholder's Equity - Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation (Detail) - shares shares in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Anti-dilutive options and RSU's excluded from EPS computation	0.2	8.7	0.5	6.4

Preferred and Common Stockhol59

Preferred and Common Stockholder's Equity - Schedule of Stock Repurchases (Detail) - USD ($) shares in Millions, $ in Millions	3 Months Ended	6 Months Ended
	Dec. 31, 2016	Dec. 31, 2016
Stockholders Equity [Line Items]
Shares purchased and retired		1.6
Common stock and additional paid-in-capital reductions	$ 5.4	$ 14.5
Charges to retained earnings	$ 4.8	$ 17.1
Common Stock [Member]
Stockholders Equity [Line Items]
Shares purchased and retired	0.6	1.6

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	Jan. 01, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2018
Income Tax Contingency [Line Items]
Income tax expense (benefit)		$ (28.4)	$ 6.2	$ (22.8)	$ 11.4
Income tax expense benefit excluding change in enacted tax rate		$ 4.2		$ 9.8
Approximate rate on pre-tax income			51.20%		70.80%
Effective income tax rate continuing operations excluding change in enacted tax rate		113.50%		10.70%
Tax Act [Member]
Income Tax Contingency [Line Items]
Income tax (benefit) due to revaluing of deferred tax liabilities		$ (32.6)
U.S. federal statutory rate				35.00%
Tax Act [Member] | Scenario, Forecast
Income Tax Contingency [Line Items]
Blended Corporate Tax Rate						28.00%
Tax Act [Member] | Subsequent Event [Member]
Income Tax Contingency [Line Items]
U.S. federal statutory rate	21.00%

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	6 Months Ended
	Sep. 30, 2014	Dec. 31, 2017	Nov. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, description		Options and restricted stock units granted to our non-employee directors vest in full upon completion of one year of service on the Board following the date of the grant.
Total unrecognized share-based compensation cost related to stock options		$ 0
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period of share-based compensation vested, years		4 years
Stock options [Member] | Share-based compensation granted after December 5, 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expire from date of grant, years		8 years
Stock options [Member] | Share-based compensation granted prior to December 5, 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expire from date of grant, years		10 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period of share-based compensation vested, years	4 years
Total unrecognized share-based compensation cost related to RSUs		$ 46.7
Total unrecognized share-based compensation cost, weighted-average period, years		2 years 4 months 25 days
Restricted Stock Units (RSUs) [Member] | Non Employee Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period of share-based compensation vested, years		1 year
The 2017 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares approved			1,400,000
The 2017 Plan [Member] | Maximum [Member] | Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grant		1,700,000
The 2010 Plan [Member] | Options and Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grant		6,800,000
2012 Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares approved		2,000,000
Shares issued under the Plan		700,000

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding (Detail) shares in Millions	6 Months Ended
	Dec. 31, 2017$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding at beginning of period, Number of shares | shares	8
Options granted, Number of shares | shares	0
Options exercised, Number of shares | shares	(0.5)
Options canceled or expired, Number of shares | shares	(0.1)
Options outstanding at end of year, Number of shares | shares	7.4
Options exercisable at end of period, Number of shares | shares	7.4
Options outstanding at beginning of period, Weighted average exercise price | $ / shares	$ 24.67
Options granted, Weighted average exercise price | $ / shares	0
Options exercised, Weighted average exercise price | $ / shares	23.39
Options canceled or expired, Weighted average exercise price | $ / shares	26.60
Options outstanding at end of year, Weighted average exercise price | $ / shares	24.75
Options exercisable at end of period, Weighted average exercise price | $ / shares	$ 24.75

Share-Based Compensation - Sc63

Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding (Detail) - Restricted Stock Units (RSUs) [Member] shares in Millions	6 Months Ended
	Dec. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs outstanding at beginning of period, Number of shares | shares	2
RSUs granted, Number of shares | shares	1.1
RSUs vested, Number of shares | shares	(0.7)
RSUs canceled, Number of shares | shares	(0.1)
RSUs outstanding at end of period, Number of shares | shares	2.3
RSUs outstanding at beginning of period, Weighted average grant date fair value | $ / shares	$ 33.02
RSUs granted, Weighted average grant date fair value | $ / shares	32.64
RSUs vested, Weighted average grant date fair value | $ / shares	34.97
RSUs canceled, Weighted average grant date fair value | $ / shares	27.40
RSUs outstanding at end of period, Weighted average grant date fair value | $ / shares	$ 32.77

Share-Based Compensation - Sc64

Share-Based Compensation - Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 6.9	$ 7.4	$ 13.3	$ 15.2
Molecular Diagnostic Testing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	0.2	0.3	0.3	0.4
Pharmaceutical and Clinical Services Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	0	0	0.1	0.1
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	1.2	1.4	2.1	3
Selling, General, and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 5.5	$ 5.7	$ 10.8	$ 11.7

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) $ in Millions	Dec. 31, 2017USD ($)
Level 3 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Estimated fair value of long-term debt	$ 38.7

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Financial Assets (Detail) - USD ($) $ in Millions		Dec. 31, 2017	Jun. 30, 2017
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets and liability		$ 35.1	$ (24.8)
Money Market Funds [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	[1]	2.8	7.4
Corporate Bonds and Notes [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		57.7	50.4
Municipal Bonds [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		34.8	36.9
Federal Agency Issues [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		12.5	13.8
US Government Securities [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		8.3	7.2
Contingent Consideration [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial liability		(81)	(140.5)
Level 1 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets and liability		2.8	7.4
Level 1 [Member] | Money Market Funds [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	[1]	2.8	7.4
Level 2 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets and liability		113.3	108.3
Level 2 [Member] | Corporate Bonds and Notes [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		57.7	50.4
Level 2 [Member] | Municipal Bonds [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		34.8	36.9
Level 2 [Member] | Federal Agency Issues [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		12.5	13.8
Level 2 [Member] | US Government Securities [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		8.3	7.2
Level 3 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets and liability		(81)	(140.5)
Level 3 [Member] | Contingent Consideration [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial liability		$ (81)	$ (140.5)
[1]	Money market funds are primarily comprised of exchange traded funds and accrued interest

Fair Value Measurements - Chang

Fair Value Measurements - Change in Fair Value of Contingent Consideration (Detail) $ in Millions	6 Months Ended
	Dec. 31, 2017USD ($)
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Balance June 30, 2017	$ 140.5
Change in fair value recognized in the income statement	(60.2)
Translation adjustments recognized in other comprehensive income	0.7
Ending balance December 31, 2017	$ 81

Employee Deferred Savings Pla68

Employee Deferred Savings Plan - Additional Information (Detail)	6 Months Ended
	Dec. 31, 2017
Compensation And Retirement Disclosure [Abstract]
Percent of employee contribution to deferred savings plan	50.00%
Employer's contribution not to exceed percentage of the employees compensation	4.00%

Employee Deferred Savings Pla69

Employee Deferred Savings Plan - Company Recorded Contributions To Plan (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Compensation And Retirement Disclosure [Abstract]
Deferred savings plan contributions	$ 1.6	$ 1.4	$ 3.5	$ 3

Segment and Related Informati70

Segment and Related Information - Additional Information (Detail)	6 Months Ended
	Dec. 31, 2017Segment
Segment Reporting [Abstract]
Number of reportable segment	2

Segment and Related Informati71

Segment and Related Information - Schedule of Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Revenues	$ 194	$ 196.5	$ 384.2	$ 373.9
Depreciation and amortization	13.1	12.9	26.3	22.1
Operating income (loss)	4.4	17	91.9	22.6
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenues	179.2	183.9	358	348.9
Depreciation and amortization	11.7	11.5	23.5	19.3
Operating income (loss)	34.6	32.1	68.6	62
Other [Member]
Segment Reporting Information [Line Items]
Revenues	14.8	12.6	26.2	25
Depreciation and amortization	1.4	1.4	2.8	2.8
Operating income (loss)	$ (30.2)	$ (15.1)	$ 23.3	$ (39.4)

Segment and Related Informati72

Segment and Related Information - Schedule of Total Operating Income for Reportable Segments (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting [Abstract]
Total operating income for reportable segments	$ 4.4	$ 17	$ 91.9	$ 22.6
Interest income	0.4	0.3	0.8	0.6
Interest expense	(0.7)	(2.6)	(1.7)	(3.3)
Other	(0.4)	(2.6)	(0.7)	(3.8)
Income before income tax	3.7	12.1	90.3	16.1
Income tax provision	(28.4)	6.2	(22.8)	11.4
Net income	32.1	5.9	113.1	4.7
Net loss attributable to non-controlling interest			(0.1)
Net income attributable to Myriad Genetics, Inc. stockholders	$ 32.1	$ 5.9	$ 113.2	$ 4.7

Supplemental Cash Flow Inform73

Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Detail) - USD ($) $ in Millions	6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Supplemental Cash Flow Elements [Abstract]
Cash paid during the period for income taxes	$ 5.5	$ 8
Non-cash investing and financing activities:
Fair value adjustment on marketable investment securities recorded to other stockholder's equity	$ (0.3)	$ (0.8)